electroCore, Inc. (ECOR): M&A transaction — electroCore completes acquisition of NeuroMetrix; $4.49/share plus CVRs

electroCore, Inc.

Cash consideration of $4.49 per NURO share; each share also gets one CVR tied to Quell sales milestones.
CVR payments include 8% of Quell Net Sales up to $500K in first year, 6% in second year, plus DPNCheck proceeds.
electroCore gains Quell Fibromyalgia Solution, expects to leverage VA Hospital System distribution channel.
NURO shares to be de-listed from Nasdaq Capital Market before trading on May 2, 2025.
Transaction approved by NURO stockholders on March 21, 2025; closed May 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

electroCore, Inc. completed an acquisition involving NeuroMetrix, Inc. for $4.49 per share in cash plus contingent value rights (closed 2025-05-01).

Action: acquisition
Counterparty: NeuroMetrix, Inc.
Consideration: $4.49 per share in cash plus contingent value rights
Closing: 2025-05-01

Exact text from the filing

a NURO RSA or NURO RSU (as such terms are defined below)), was canceled and converted into the right to receive from the Surviving Corporation (i) an amount in cash equal to $4.49 per share of NURO Common Stock (the “ Per Share Cash Consideration ”) and (ii) one contingent value right (a “ CVR ”), representing the right to receive the Contingent Payments

View on SEC.gov

Browse all m&a transactions →

electroCore, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-008177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.